With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...

S &P 500 giants Eli Lilly LLY and JPMorgan Chase JPM are stocks to watch this coming week. So is Interactive Brokers IBKR, ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

NEW YORK (AP) — The U.S. stock market sank from its record heights on Thursday, as Wall Street sifted through mixed ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

This proprietary system employs specialized algorithms to identify early signs of litigation trends in federal litigation filings. Click here to learn more about Law.com Radar's new suit alerting and ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide ...